|Description||AMG-548 is a selective p38α inhibitor with Ki value of 0.5nM. It displays >1000-fold selectivity against 36 other kinases, and it can inhibit whole blood LPS-stimulated TNFα. In Sep 2008, Preclinical for Rheumatoid arthritis in USA was discontinued.|
|Solubility||Soluble in DMSO|
|Application||Inflammation; Rheumatoid arthritis|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Amgen|
PH-797804 is a diarylpyridinone inhibitor of p38 mitogen-activated protein (MAP) kinase. PH-797804 exhibited exceptionally high specificity against MAP kinases ...
VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that ...
VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β.
SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM.
Acumapimod is a P38 mitogen-activated protein kinase inhibitor with IC50 value of less than 1 μM for p38α. Phase II clinical trials for the treatment of Chronic...
SD-06 is an inhibitor of p38α (IC50=170 nM).
SB 202190 is a potent inhibitor of p38 MAPK. It inhibits the p38α and β isoforms with IC50 of 50 nM/100 nM at SAPK2a/p38 and SAPK2b/p38β2.
SKF-86002 is a p38 MAP kinase inhibitor, the IC50 is 0.1 - 1 μM. It potently inhibits LPS-induced IL-1 and TNF-α production in human monocytes, the IC50 is1 μM....
SB239063 is a potent p38MAPK inhibitor. SB 239063 had an IC(50) of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated...
TA-02 is a p38 MAPK inhibitor ( IC50 = 20 nM ).
BMS582949 is a potent and selective P38 mitogen-activated protein kinase (P38 MAPK) inhibitor with IC50 value of 13nM, which plays a crucial role in regulating ...
TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK...
FR-167653, a pyrazolotriazin derivative, has been found to be a cytokine inhibitor as well as P38 mitogen-activated protein kinase inhibitor and was once studi...
SB202190, also named FHPI, under the IUPAC name 4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one, is a pyridinyl imid...
RPR-200765A Mesylayte, a potent and selective inhibitor of p38 MAP kinase (IC50 = 50 nM), could exhibit a profile of disease modifying activity in rheumatoid ar...
CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...
Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an important role in the developm...
p38 MAPK-IN-1, a naphthyridine N-oxide, is a novel potent and selective inhibitor of p38 MAPK and it was found to have proper balance between potency and pharma...
UPC-K-005 is a novel small-molecule inhibitor of a new allosteric site in p38α (IC50 = 13 mcM), which is the binding site for MAPK-activated protein kinase 2 (M...